Shinichiroh Maekawa

Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance

M. Ozaki, N. Yamamoto, T. Kamitani, 2022, Cancer science.

Real‐world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all‐case postmarketing surveillance in Japan

M. Ozaki, N. Yamazaki, A. Shimizu, 2022, The Journal of dermatology.

Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan

R. Ueno, Shinichiroh Maekawa, Asuka Watanabe, 2021, Clinical Drug Investigation.

Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan

Shinichiroh Maekawa, Asuka Watanabe, Masahiro Kimata, 2023, Infectious Diseases and Therapy.

Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study

T. Ota, Shinichiroh Maekawa, Keiko Ikeda, 2020, Advances in Therapy.

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance

N. Yamamoto, Yuichiro Ito, M. Ozaki, 2023, BMC Cancer.

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan

Shinichiroh Maekawa, Asuka Watanabe, Masahiro Kimata, 2024, Infectious diseases and therapy.